Cassava Sciences | PTIE - Ebit


Cassava Sciences reported $-11.17M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
Abbott USD 1.36B 775M Sep/2026
Amgen USD 4.61B 777M Jun/2026
Biogen USD 419.5M 663.3M Sep/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Cassava Sciences USD -11.17M 2.38M Mar/2026
Eisai JPY 24.73B 35.04B Jun/2026
Eli Lilly USD 13.09B 635M Sep/2026
Geron USD -236K 10.55M Mar/2026
J&J USD 6.47B 1B Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Novartis USD 4.73B 549M Jun/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD -180M 5.16B Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026